Author:
Eisman John A,Bone Henry G,Hosking David J,McClung Michael R,Reid Ian R,Rizzoli Rene,Resch Heinrich,Verbruggen Nadia,Hustad Carolyn M,DaSilva Carolyn,Petrovic Romana,Santora Arthur C,Ince B Avery,Lombardi Antonio
Subject
Orthopedics and Sports Medicine,Endocrinology, Diabetes and Metabolism
Reference26 articles.
1. National Osteoporosis Foundation http://nof.org/advocacy/prevalence/index.htm
2. Cathepsin K inhibitors: a novel target for osteoporosis therapy;Stoch;Clin Pharmacol Ther.,2008
3. Effect of one year treatment with the cathepsin-K inhibitor, balicatib, on bone mineral density (BMD) in postmenopausal women with osteopenia/osteoporosis;Adami;J Bone Miner Res.,2006
4. Effect of three month treatment with the cathepsin-K inhibitor, balicatib, on biochemical markers of bone turnover in postmenopausal women: evidence for uncoupling of bone resorption and bone formation;Papanastasiou;J Bone Miner Res.,2006
5. A highly potent inhibitor of cathepsin K (relacatib) reduces biomarkers of bone resorption both in vitro and in an acute model of elevated bone turnover in vivo in monkeys;Kumar;Bone.,2007
Cited by
224 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献